Toronto, Ontario (PRWEB) December 20, 2013
Hemostemix Ltd. announced today the formation and inaugural meeting of a clinical trial steering committee to guide the company in optimizing all aspects of the upcoming Phase 2 trial for its lead product, ACP-01, in patients with critical limb ischemia.
As well-respected specialists in critical limb ischemia and vascular surgery, the role of the Clinical Trial Steering Committee will be to advise the Company on all matters critical to the trial’s success.
“We are extremely honored with the caliber of key opinion leaders who have committed to providing us with their expertise on the trial’s design, implementation, sites, enrollment criteria, and several other critical parameters,” stated Hemostemix Founder and President, Dr. Valentin Fulga.
“We believe we have a real opportunity to learn valuable lessons from the committee’s collective experience in the space and translate that into a successful trial. The committee is providing valuable input in this regard,” continues Dr. Fulga, “and we were pleased to have what proved to be a very valuable inaugural meeting this week in Toronto.”
The committee is comprised of prominent clinician scientists, namely:
Copyright©2012 Vocus, Inc.
All rights reserved